Skip to main content
. 2018 May 28;9:1078. doi: 10.3389/fimmu.2018.01078

Figure 1.

Figure 1

Simultaneous administration of MIS416 and human adult stem cells, including umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs) enhances therapeutic effects of the cells against experimental colitis. Mice were exposed to 3% dextran sulfate sodium (DSS) in their drinking water for 7 days and injected intraperitoneally hUCB-MSCs at day 1, and MIS416 at day 1 and 8 through retro-orbital route. (A) Scheme for the experimental design. (B) Survival rates of the mice were monitored. (C) Changes in body weights were measured daily. (D) Disease activity index for colitis severity. (E) On day 11, colon length of mice was measured by gross examination. n = 10–22 mice per group, three independent animal experiments were performed. (−): negative control group, (+): DSS administered group, U: hUCB-MSCs-treated group, M: MIS416-treated group, U + M: hUCB-MSCs and MIS416 co-treated group. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001. Results are shown as the mean ± SEM.